Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
Open Access
- 13 April 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 47 (7), 639-646
- https://doi.org/10.1093/jjco/hyx049
Abstract
Nivolumab improved overall survival (OS) and objective response rate (ORR) versus everolimus in previously treated patients with advanced renal cell carcinoma in the phase III CheckMate 025 study (minimum follow-up: 14 months). We report efficacy and safety in the global and Japanese populations (minimum follow-up: 26 months). Patients were randomized 1:1 to receive nivolumab 3 mg/kg intravenously every 2 weeks or everolimus 10-mg tablet orally once daily. Primary endpoint: OS, key secondary endpoints: ORR, progression-free survival and safety. Of 410 (nivolumab) and 411 (everolimus) patients, 37 (9%) and 26 (6%), respectively, were Japanese. Median OS for the global population was 26.0 months (nivolumab) and 19.7 months (everolimus; hazard ratio 0.73 [95% confidence interval [CI]: 0.61–0.88]; P = 0.0006), with medians not reached for Japanese patients. ORR for the global population was 26% (nivolumab) versus 5% (everolimus; odds ratio 6.13; 95% CI: 3.77–9.95); ORR for Japanese patients: 43% versus 8% (odds ratio 9.14; 95% CI: 1.76–88.33). In Japanese patients, any-grade treatment-related adverse events (AEs) occurred in 78% (Grade 3–4, 19%; most common, anemia [5%]) treated with nivolumab and 100% (Grade 3–4, 58%; most common, hypertriglyceridemia [12%]) treated with everolimus; the most common with nivolumab was diarrhea (19%) and with everolimus was stomatitis (77%). Quality of life was stable in the nivolumab arm. With >2 years of follow-up, Japanese patients had a higher response rate with nivolumab versus everolimus that was more pronounced yet consistent with the global population, with median OS not reached, and a favorable safety profile.Keywords
Funding Information
- Bristol-Myers Squibb
- Ono Pharmaceutical Company Limited
This publication has 21 references indexed in Scilit:
- Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trialThe Lancet Oncology, 2016
- Pharmacotherapies for renal cell carcinoma in JapanInternational Journal of Urology, 2015
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Use of Targeted Therapies for Advanced Renal Cell Carcinoma in the Asia-Pacific Region: Opinion Statement From China, Japan, Taiwan, Korea, and AustraliaClinical Genitourinary Cancer, 2014
- Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart reviewInternational Journal of Oncology, 2013
- Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinomaAnti-Cancer Drugs, 2013
- Kidney Cancer Working Group ReportJapanese Journal of Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Development and Validation of a Scale to Measure Disease-Related Symptoms of Kidney CancerValue in Health, 2007
- A Confidence Interval for the Median Survival TimePublished by JSTOR ,1982